Why Choose Ace Therapeutics' In Vivo Screening Services for Ocular Biomarkers?

Biomarkers have been widely incorporated into preclinical research because they can increase the chances of successful drug discovery while avoiding the high attrition rate of drugs during clinical translation. As a comprehensive service provider of ophthalmology solutions, Ace Therapeutics is committed to providing global customers with early-stage biomarker discovery and services, and obtaining corresponding in vitro and in vivo models to better guide clinical transformation.

At Ace Therapeutics, our team of ocular biomarker experts provides flexible in vivo ocular biomarker screening services to clients globally, often using our multi-omic biomarker analysis platform, powerful bioinformatics and proprietary validation strategies and utilizes a range of preclinical live animal models relevant to ocular diseases.

Similarly to in vitro screening services for ocular biomarkers, our in vivo screening services for ocular biomarkers evaluate the sample status of responder and nonresponder groups after study drug treatment. This step is mainly based on our multi-omics analysis platform and powerful bioinformatics data processing capabilities. Finally, potential biomarkers that can be used for downstream decision-making were discovered according to differences in sample status and hypotheses were validated.

Possible Models for Your Research Needs

Ace Therapeutics has a comprehensive system of preclinical live animal models, including rats, mice, rabbits, dogs, zebrafish, etc. Its research areas include but are not limited to:

• Allergic conjunctivitis
• Dry eye syndrome
• Laser-induced choroidal neovascularization
• Hereditary retinopathy
• Endotoxic uveitis
• Corneal sensitivity
• Retinopathy is caused by oxidation
• Cataract
• Acute and chronic glaucoma
• Retinopathy of prematurity
• Diabetic retinopathy
• Wet and dry AMD
• Custom model

What appeals to our clients is that each of our models is supported by a range of translational tools, including biomarkers, in vitro/in vivo assays and in silico simulations. This allows us to optimize lead drugs. In addition, we also develop customized in-vivo models according to the project needs of our customers.

Ace Therapeutics scientists use a suite of validated in vivo models to understand the mechanism of action and underlying pharmacology of a client's drug candidate. Accurate measurement of drug efficacy can be provided by our ocular biomarker in vivo screening service, which is beneficial for biomarker discovery. Our ocular biomarker in vivo screening services can address the following questions, including but not limited to:

• Explore/validate the mechanism of action of drug candidates through in vivo screening services for ocular biomarkers.
• Identify genetic traits associated with drug response.
• Development of biomarkers.
• Guide clinical trials.

In the field of ocular biomarker research, Ace Therapeutics has demonstrated outstanding results. Our expert team has successfully developed ocular biomarkers for many pharmaceutical companies and research institutions to meet their scientific research needs. If you are conducting ophthalmology research and looking for related in vivo ocular biomarker screening services, Ace Therapeutics is the place for you. Please feel free to contact us. We look forward to becoming your trustworthy partner.

• In Vitro Screening Services for Ocular Biomarkers
• Ocular Candidate Biomarker Optimization Services
• Potential Ocular Biomarker Validation Services

• * Name:
• Phone:
• * Email:
• * Services or Products of Interest:
• Project Description:
• * All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

  * Tick to confirm the Research Use Only (RUO) statement.

• Submit